Navigation Links
Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008

ARLINGTON, Va., March 6 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a development stage biotechnology company, announced today its third quarter financial results. Full details of the Company's financial results are available in the Company's Form 10-QSB at

For the three months ended January 31, 2008 the Company reported net income of $611,006 and earnings per share of $0.02 compared to a net loss of $37,198 and loss of $0.00 per share for the comparable period one year ago. For the nine months ended January 31, 2008, the Company reported net income of $474,011 and earnings per share of $0.02 compared to a net loss of $74,086 and loss of $0.00 per share for the comparable period one year ago. In the nine months period that ended January 31, 2008, the Company began its operations as a biotechnology company while in the nine months ended January 31, 2007, it had no biotechnology operations.

The Company's total operating revenues were $924,940 for the three months ended January 31, 2008 and $1,174,940 for the nine months ended January 31, 2008. The Company generated revenues for the nine months ended January 31, 2008 providing oncology services. For the three months ended January 31, 2007 and for the nine months ended January 31, 2007 the Company generated no revenues.

For the three months ended January 31, 2008, expenses were $319,998 compared to $37,198 for the comparable period one year ago. For the nine months ended January 31, 2008, expenses were $716,986 compared to $74,086 for the comparable period one year ago. The increased expenses for the three and nine months ended January 31, 2008 represented the Company moving forward in executing its new business plan of building a biotechnology company.

"I am greatly encouraged by the Company's revenue growth in our first year of operations. This performance helps build a solid foundation for our future as we hope to rise to prominence quickly to become a major biotech player," said James Martell, President and CEO of Champions Biotechnology. "It is quite exceptional for a biotech company to generate revenues and earnings at such an early developmental stage."

Champions Biotechnology is actively engaged, as stated in the Company's 10-QSB filing, in pursuit of funding to accelerate the development of the Company's preclinical platform and drug portfolio, development of a management team, selection and appointment of new members to the Board of Directors and formation of a Scientific Advisory Board. The Company looks forward to reporting updates regarding any material events and corporate changes in the future.

About Champions Biotechnology, Inc.

Champions Biotechnology Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs for companies and physicians. The Company believes that its preclinical platform is a novel approach based upon the direct implantation of primary human tumors in immune deficient mice and propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Biomerk Tumorgrafts(TM), unlike cell line derived xenografts used in traditional preclinical testing, are never passaged in cell tissue culture.

The Company believes that these Tumorgrafts more closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients. The Company plans to leverage the preclinical platform to evaluate drug candidates and develop a portfolio of novel therapeutic candidates through pre-clinical trials. If drugs reach this early stage of development, the Company intends to sell, partner with or license them to pharmaceutical and/or biotechnology companies, as appropriate. Management believes this strategy will enable the Company to maximize its return on investment in a relatively short time frame. The Company also offers its preclinical platform and predictive tumor data to physicians for personalized patient care and to companies for a more predictive evaluation of oncology drugs in models that integrate drug evaluation with biomarker discovery.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.

SOURCE Champions Biotechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Leading-edge body sensor could help produce sporting champions
2. Six Olympic Legends Battling Chronic Diseases Lead Revolution in Advancing Pharmacy Care as Medco Launches the Tour of Champions
3. 18th Annual CATCH Night of Champions Raises $225,000 To Help Support Local Youth
4. 2007 Ottawa & Eastern Ontario Physique Championship to be Sponsored by Natural Nutrition
5. Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Childrens Research Hospital(R)
6. The physiology of champions
7. Natural Nutritions Spokesperson and Athlete Natalie Waples Wins 2008 Arnold Amateur Figure Championship
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and ... diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians can ... from their electronic medical record (EMR) without the need for redundant patient entry ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... , ... November 26, 2015 , ... PRMA Plastic Surgery ... 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What ... up every day excited to rebuild lives and it’s an honor to have served ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ... These classically-influenced trailer titles work with any font, giving users limitless opportunities to ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
(Date:11/27/2015)... Nov. 26, 2015 ... of the "2016 Global Tumor Marker ... Volume and Sales Segment Forecasts, Innovative Technologies, ... report to their offering. --> ... the "2016 Global Tumor Marker Testing ...
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
Breaking Medicine Technology: